App Store

Google Play

DK - Details page - Device banner - 894x1036

Nyd den ubegrænsede adgang til tusindvis af spændende e- og lydbøger - helt gratis

Lyt når som helst, hvor som helst 

CNBC

From the open to the close, “Closing Bell” and “Closing Bell: Overtime” have you covered. From what’s driving market moves to how investors are reacting, Scott Wapner, Morgan Brennan and Jon Fortt guide listeners through each trading session and bring to you some of the biggest names in business.

Closing Bell

From the open to the close, “Closing Bell” and “Closing Bell: Overtime” have you covered. From what’s driving market moves to how investors are reacting, Scott Wapner, Jon Fortt, Morgan Brennan and Michael Santoli guide listeners through each trading session and bring to you some of the biggest names in business.

Closing Bell: Nvidia Probe, iPhone Revenue & The Mag 7 Trade 12/9/24

The Nasdaq takes center stage with major earnings reports from Oracle, MongoDB, and C3 AI. Jefferies Analyst Brent Thill joins to break down Oracle's results, while C3 AI CEO Tom Siebel offers insights on his company’s performance. Mobileye CEO Amnon Shashua shares key takeaways from Investor Day and the company’s China business. Plus, a market panel featuring Jill Carey Hall of BofA and Dana D’Auria of Envestnet discusses the state of SMID-cap strategy.

Closing Bell Overtime: Mobileye CEO Shares Growth Plan and Highlights from Capital Markets Day; C3 AI CEO On Blowout Quarter 12/9/24

Closing Bell: The Lay of the (Soft) Landing, Tech Run or Retreat? 12/10/24

After stocks slid into the close today, our panel discussion with Adam Crisafulli of Vital Knowledge and Patrick Fruzzetti of Rose Advisors give you the market trends you need to know. Anu Aiyengar, J.P. Morgan's Global Head of M&A, shares insights on the state of deal-making and the driving force behind the recent flurry of announcements. Plus, interviews with Howard Hughes CEO David O'Reilly on meeting house demand and Cohesity CEO Sanjay Poonen closing the deal for Veritas’ enterprise data protection business unit—and what’s next on the road to an IPO. Key earnings reports from GameStop and Dave & Buster's and a deep dive explores how Taylor Swift’s record-breaking tour is transforming the entertainment industry.

Closing Bell Overtime: Cohestiy CEO On Closing Key Acquisition; JPMorgan Global Head Of M&A On Dealmaking Activity Turnaround 12/10/24

The mega-cap melt up rolls on … so what is next for stocks? Fundstrat’s Tom Lee breaks down his outlook for 2025. Plus, former Dallas Fed President Richard Fisher tells us what today’s CPI print could mean for the Fed’s next move. And, Deirdre Bosa explains what is behind the big drop in Uber’s stock today.

Closing Bell: Tech Surge Back with a Vengeance 12/11/24

Today's show dives into Adobe's latest earnings with insights from Chair and CEO Shantanu Narayen. Schwab Senior Investment Strategist Kevin Gordon and Brooke May, managing partner at May Evans Wealth, hit key trends shaping the market action, while Citi's Drew Pettit unpacks the bank’s 2025 playbook for U.S. equity strategy. Plus, updates on the anticipated ServiceTitan IPO and Sarah Levy, Betterment CEO, on markets and retirement. Morgan goes deep on the intersection of venture capital and defense technology.

Closing Bell Overtime: Adobe CEO On Earnings, Guidance; Citi’s 2025 Playbook 12/11/24

United Launch Alliance, a joint venture between Lockheed Martin and Boeing, blasted into 2025 with the launch of its long-awaited Vulcan Centaur rocket earlier this year. With a long history of launching national security missions, the company is now moving into commercial markets with the help of Vulcan and contracts with the likes of Amazon. ULA CEO Tory Bruno joins Morgan Brennan from the Reagan National Defense Forum to discuss the evolving launch market, what Trump 2.0 will mean for commercial space, and what the future of Boeing’s commercial space will mean for the company.

Manifest Space: The Future of Vulcan, National Security & Space Under Trump 2.0 with United Launch Alliance CEO Tory Bruno 12/12/24

Closing Bell: Positioning for Trump 2.0 12/12/24

Today's coverage kicks off with a market panel featuring Barbara Doran of BD8 Capital Partners and Phil Camporeale of J.P. Morgan Asset Management. Earnings highlights include RH, Broadcom, and Costco, with expert analysis from Bernstein’s Stacy Rasgon on Broadcom and DA Davidson’s Michael Baker on Costco. Globalstar CEO Paul Jacobs discusses investor day developments and reports of Apple Watch integration. Our Angelica Peebles reports on Vertex Pharmaceuticals’ non-opioid pain medication and its potential market impact.

Closing Bell Overtime: Globalstar CEO on Apple Integration Reports; RH, Broadcom, and Costco Earnings 12/12/24

Will stocks run or limp to the finish line this year? Perhaps the answer lies in what happens with tech which has seen a resurgence. We break down the big move in Broadcom and Apple’s massive run to $4 trillion. Plus, Payne Capital’s Courtney Garcia, NB Private Wealth’s Shannon Saccocia and JPMorgan Asset Management’s Jordan Jackson tell us what they’re forecasting for stocks. And, Former Cleveland Fed President Loretta Mester breaks down what she is expecting from the Fed next week – and what it is at stake for the economy.

Closing Bell: Navigating the Big Tech Bounce 12/13/24

The Nasdaq and S&P 500 snapped their winning streaks after comments from Fed Chair Jay Powell and a weak 30-year auction. Barclays Head of US Equity Strategy Venu Krishna breaks down the market action. Eli Lilly CEO David Ricks joins in an exclusive interview to discuss the company’s weight-loss drug getting FDA approval. CFRA analyst Zach Warring breaks down Wynn’s earnings. Oakmark’s Bill Nygren on his top value picks heading into the year end. Plus, NBER Director John Lipsky on the path forward on inflation.

Closing Bell Overtime: Exclusive Interview With Eli Lilly CEO After Weight Loss Drug Gets FDA Approval; Oakmark’s Bill Nygren Gives Top Value Picks 11/9/23

Closing Bell Overtime: Exclusive Interview With Eli Lilly CEO After Weight Loss Drug Gets FDA Approval; Oakmark’s Bill Nygren Gives Top Value Picks 11/9/23

Lyt når som helst, hvor som helst

Other podcasts you might like ...